Sleep apnea and related hypoxia more severe in obstructive sleep apnea patients with cancer compared with those without cancer
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
Study findings suggest that PSMA PET results may alter treatment decisions in high-risk prostate cancer.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Investigators estimated disease trajectory and outcomes up to 30 years after the start of prostate cancer active surveillance.
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
Researchers sought to determine if genetic risk score could identify risk of prostate cancer in men with LUTS.
MDT significantly prolonged progression-free survival, with the largest effect observed among patients with tumors harboring high-risk genetic mutations.